Abbott doesn't typically wade into early-stage quantum technology. The diagnostic giant prefers sure things—mature platforms with clear regulatory pathways and proven markets. Which makes its decision to anchor a $55 million Series B for a German quantum-MRI startup all the more striking.
NVision Quantum Technologies, a company most people outside of specialized radiology circles have never heard of, announced the round on May 13, 2026. Abbott came in as the sole strategic investor in diagnostics, a rare configuration that suggests the medical-device giant sees something worth staking a claim on before competitors arrive. The Ulm-based firm raised $38 million in equity and secured a $17 million venture loan from the European Investment Bank, bringing the total to $55 million.
The money will fund an aggressive rollout: NVision intends to place its POLARIS quantum-enhanced MRI systems at roughly 20 cancer centers across the U.S., Europe, and Asia by year's end. Memorial Sloan Kettering, the University of Cambridge, and Technical University of Munich are already installing units—a roster that reads like a wish list for any med-tech company chasing clinical validation.
What POLARIS Actually Does
Strip away the quantum jargon and POLARIS is, essentially, a machine that makes certain molecules light up far more brightly on conventional MRI scanners. The trick lies in parahydrogen-induced polarization, a room-temperature process that hyperpolarizes metabolic imaging agents without the bulky cryogenic gear traditional systems demand. The result: ready-to-inject doses in three minutes, with signal enhancement the company pegs at more than 10,000-fold.
For oncologists, the promise is straightforward, if ambitious. Standard MRI tracks anatomy—the size and shape of a tumor. POLARIS tracks metabolism: how aggressively a cancer is consuming nutrients, how quickly it's responding to chemotherapy. In theory, that means doctors could spot treatment failure days or weeks earlier than they do now, when structural changes finally become visible on a scan.
Whether that holds up in large-scale clinical use remains an open question. But it's the kind of claim that gets diagnostics executives interested, particularly as precision oncology becomes less about one-size-fits-all protocols and more about real-time adjustments.
Abbott's Quiet Quantum Pivot
Abbott's involvement is perhaps the clearest signal yet that quantum sensing—long confined to physics labs and speculative venture pitches—is edging toward commercial viability in medicine. Peter Karabatsos, an Abbott executive whose statement accompanied the announcement, framed the partnership as part of a broader focus on "next-generation diagnostics platforms" capable of transforming treatment monitoring.
Translation: Abbott thinks this could actually work, and wants positioning before the market materializes.
Joining Abbott in the round were Playground Global, Matterwave (the deep-tech arm of b2venture), and Entrée Capital, the latter of which has backed NVision since earlier stages. Ran Achituv of Entrée Capital noted the platform's potential to "bridge quantum sensing and drug development workflows," corporate-speak for a vision in which imaging data feeds directly into pharma R&D pipelines.
Scaling Beyond the Lab
NVision has been methodically building infrastructure. In March, the company opened a strategic European hub at Cambridge's Department of Radiology. The same month, it landed a €5.4 million grant from Denmark to push quantum-enhanced MRI for early liver cancer detection—one piece of €35 million in cumulative public funding the startup has pulled in.
CEO Sella Brosh, an M.D. who co-founded the company in 2015, said the fresh capital will scale manufacturing and widen the deployment footprint. The company now employs nearly 150 people, a headcount that reflects the challenge of commercializing hardware-intensive quantum systems rather than software plays.
A Second Bet: Quantum Computing for Drug Discovery
Buried in the Series B announcement was news of PIQC—short for Photonic Integrated Quantum Circuits—a separate platform aimed at drug discovery and validation through quantum computing. The unveiling suggests NVision sees itself as more than a medical-imaging company, though commercial timelines for PIQC remain hazy at best.
Peter Barrett of Playground Global, which led NVision's $30 million Series A back in June 2023, highlighted the potential for "feedback loops between molecular imaging data and in-silico drug screening." It's an appealing narrative: use quantum sensors to understand disease in patients, then use quantum computers to design molecules that target what the sensors reveal.
Appealing, but unproven. And in a sector where regulatory approval timelines stretch across years, dual-platform ambitions carry execution risk.
The Valuation Question
Media reports around the raise put NVision's valuation near $250 million, a media-estimated figure the company hasn't confirmed. What's clear: with the EIB loan and equity combined, the startup has now raised north of $120 million in private capital since inception, alongside substantial public grants from Germany, the EU, and Denmark.
That's significant dry powder for a company operating at the intersection of quantum physics and clinical medicine—two domains not known for rapid commercialization. The Series A in 2023 also came with $19.5 million in German government funding and partnerships with Siemens Healthineers and Memorial Sloan Kettering, a partnership roster that has only deepened since.
Whether POLARIS becomes a standard tool in oncology departments or remains a specialized research instrument will likely depend on variables beyond NVision's control: reimbursement policies, physician adoption curves, and the messy realities of integrating novel technologies into entrenched clinical workflows.
For now, though, Abbott's backing offers something money alone can't buy—credibility with the establishment. And in medical devices, that often matters more than the technology itself.
